Status: Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Participants needed: 1,156
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: KaileraUpdated: Sep 3, 2026Locations: 167
Eligibility criteria
Diagnosis of type 2 diabetes mellitus (T2DM). [+3]
Current diagnosis or history of type 1 diabetes mellitus (T1DM) or any other typ... [+11]